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Abstract
Background: The visceral (VAT) and subcutaneous (SCAT) adipose tissues play different roles in physiology and obesity. The
molecular mechanisms underlying their expansion in obesity and following body weight reduction are poorly defined.
Methodology: C57Bl/6 mice fed a high fat diet (HFD) for 6 months developed low, medium, or high body weight as
compared to normal chow fed mice. Mice from each groups were then treated with the cannabinoid receptor 1 antagonist
rimonabant or vehicle for 24 days to normalize their body weight. Transcriptomic data for visceral and subcutaneous
adipose tissues from each group of mice were obtained and analyzed to identify: i) genes regulated by HFD irrespective of
body weight, ii) genes whose expression correlated with body weight, iii) the biological processes activated in each tissue
using gene set enrichment analysis (GSEA), iv) the transcriptional programs affected by rimonabant.
Principal Findings: In VAT, ‘‘metabolic’’ genes encoding enzymes for lipid and steroid biosynthesis and glucose catabolism
were down-regulated irrespective of body weight whereas ‘‘structure’’ genes controlling cell architecture and tissue
remodeling had expression levels correlated with body weight. In SCAT, the identified ‘‘metabolic’’ and ‘‘structure’’ genes
were mostly different from those identified in VAT and were regulated irrespective of body weight. GSEA indicated active
adipogenesis in both tissues but a more prominent involvement of tissue stroma in VAT than in SCAT. Rimonabant
treatment normalized most gene expression but further reduced oxidative phosphorylation gene expression in SCAT but
not in VAT.
Conclusion: VAT and SCAT show strikingly different gene expression programs in response to high fat diet and rimonabant
treatment. Our results may lead to identification of therapeutic targets acting on specific fat depots to control obesity.
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Introduction
Obesity is characterized by an increase in white fat mass, which
results from an excess in food intake relative to energy
expenditure. It is often associated with insulin resistance,
dyslipidemia and hypertension, a cluster of conditions referred to
as the metabolic syndrome, which is a major risk factor for the
development of type 2 diabetes and cardiovascular diseases.
The increase in adipose tissue mass results from fat cells
enlargement due to increased lipid storage, but also from
recruitment and differentiation of adipocyte precursors [1–3].
Expansion of adipose tissue is associated with a remodeling of the
extracellular matrix (ECM) and angiogenesis [4], events triggered
by the production, by adipocytes, of ECM proteins and remodeling
proteasessuchasmembers of the matrixmetalloproteinase(MMPs),
their inhibitors (TIMPs) [5–7], or cathepsins [8,9] and the
production of angiogenic factors such as VEGF or leptin [10–12].
Storage of fat in adipose tissue is limited and exceeding this
capacity leads to accumulation of lipids in other tissues, in
particular muscle, liver, and the endocrine pancreas, and to the
secretion by adipocytes of various adipokines. Ectopic fat
accumulation and adipokines then combine to worsen insulin
resistance and to induce beta-cell secretory dysfunctions [13–15]
[16]. Remarkably, increasing the capacity of fat tissue to store
lipids in ob/ob mice by transgenic overexpression of adiponectin
leads to massive obesity but improved metabolic control secondary
to reduced ectopic fat deposition [17]. Improvement of the
metabolic syndrome can also be achieved by reducing adiposity.
For instance, pharmacological treatment with the cannabinoid
receptor 1 (CB1) antagonist rimonabant induces weight loss in
obese rodents [18] and human [19,20]. This effect is mediated by
a modulation of the hypothalamic melanocortin pathway, which
increases energy expenditure [21,22] but possibly also through the
regulation of adipocyte differentiation and function [23,24]. Thus,
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3385the control of total fat mass and the mechanisms limiting fat tissue
expansion are intimately linked in the control of metabolic disease
progression.
The adipose tissue consists, however, of several depots, located
at different anatomical sites [25], which may originate from
distinct precursors [26,27], and which have different physiological
functions and pathophysiological roles [28]. The visceral, as
opposed to the subcutaneous adipose depots, may contribute more
to the defects associated with the metabolic syndrome [29,30].
This may result from a more rapid turnover of lipids [31] [32] and
to the direct venous drainage from the visceral fat to the liver [33].
On the other hand, a certain amount of subcutaneous fat appears
to be beneficial for longevity and health in ageing people whereas
visceral fat is detrimental [34].
Mouse models of diet-induced obesity are considered to be
relevant to the study of human obesity. In previous studies, we
showed that genetically homogenous C57Bl/6 mice fed a HFD
develop various degrees of glucose intolerance and obesity. In
large cohorts, approximately 50% of the mice become obese and
diabetic, ,15% remain lean but glucose intolerant, ,15% remain
lean with a normal glucose tolerance, and the rest of the mice have
intermediate phenotypes [35]. This differential metabolic adapta-
tion to the same feeding conditions may be caused by yet
uncharacterized epigenetic modifications [36,37].
Here, we fed C57Bl/6 mice a high fat diet for 6 months and
mice with different body weights but similar levels of glucose
intolerance were then treated with vehicle or rimonabant for one
month to normalize body weight. We then performed transcrip-
tomic analysis of the visceral (VAT) and subcutaneous (SCAT)
adipose tissues from each mouse group. This experimental design
allowed us to identify genes regulated by HFD irrespective of body
weight gain, genes whose expression was associated with increased
body weight, and genes that were normalized by rimonabant
treatment. Together our data show strikingly different adaptation
of both VAT and SCAT to high fat diet, suggesting that largely
different tissue remodeling events take place for expansion of both
fat depots and their normalization by rimonabant treatment. Our
data may provide new targets for regulating selectively visceral or
subcutaneous fat development in obesity.
Results
Physiological characterization of HFD fed mice treated or
not with rimonabant
Mice were fed a normal chow or a high fat diet for 6 months
and their body weight and tolerance to an intraperitoneal glucose
injection were measured. These parameters showed that the
adaptation of each mouse to the HFD was very heterogeneous
(Figure 1), as previously described [35]. For the subsequent
transcriptomic study, we selected mice (boxes in Figure 1) that
were similarly glucose intolerant but with low (L), medium (M) or
high (H) body weight. The normal chow-fed mice (NC, open
squares in Figure 1) were used as a reference. At six months of
HFD or NC feeding mice in each group were randomly
distributed into two subgroups, and received either a daily oral
administration of rimonabant or vehicle for 24 days, while
remaining on either the HFD or NC diet. As shown in Figure 2,
this led to a remarkable correction of body weight in each of the
HFD mouse group but no change in body weight in NC mice. The
body weight of the mice from each HFD group treated with
rimonabant was not different no longer different from that of the
NC group at the end of the treatment. In the H group this was
associated with a correction of basal glycemia and insulinemia
(Figure 3A, B), a significant reduction in leptin levels and a
tendency to normalize plasma VLDL (Figure 3C, D). Adipocyte
cross-sectional area in the VAT and SCAT was also assessed in
each group of mice (Figure 4A,C). There was a direct correlation
between body weight and mean cross-sectional area in both
tissues, suggesting that adipocyte hypertrophy is an important
contributor of fat tissue expansion. This hypertrophy was
corrected by rimonabant treatment in all groups (Figure 4B,D).
Analysis of genes regulated by HFD
Microarray experiments and statistical analysis. Total
RNA was prepared from visceral and subcutanous adipose tissues
from the L, M, H and the NC mouse groups, treated with vehicle
or rimonabant. Transcript profiling was performed using
microarrays containing 17’664 mouse cDNAs. The filtered data
for each group of HFD mice were then analyzed as shown in
Figure 5. Geneset enrichment analysis (GSEA) was conducted on
the filtered data. Separately, statistical analysis was performed to
identify the effect of HFD on gene expression. This analysis was
performed, firstly, to search for genes whose expression was
regulated irrespective of body weight, comparing the NC group
with the L, M and H mice considered as a unique HFD group
(‘‘Grouped analysis’’). Secondly, we identified genes that were
significantly regulated by HFD in each of the L, M or H groups
(‘‘Individual analysis’’) and searched, by linear regression analysis
those whose expression level was correlated with body weight. The
genes that were affected by rimonabant treatment were also
identified from these gene sets. The pathways over-represented in
each gene set were analyzed by KEGG analysis and Gene
Ontology using the David database system.
Figure 6 shows a global representation of the number of genes,
with their expression level (M value), that were up- or down-
regulated irrespective of body weight gain in VAT and SCAT
(Fig 6A,C) and those whose expression was regulated in proportion
to body weight gain in both tissues (Fig 6B,D). The figure shows
that both tissues responded differently to HFD. There were many
more genes that were either up- or down-regulated by HFD
Figure 1. Effect of high fat diet on body weight and glucose
intolerance. Mice were fed for 6 months with a normal chow (open
squares) or a high fat diet (closed squares) and their body weight and
tolerance to intraperitoneal glucose injection (AUC glucose) were
assessed. The figure shows the heterogenous adaptation of C57Bl/6
mice to the HFD. Groups of mice (in squares) with low (L), medium (M),
or high (H) final body weight but with similar glucose intolerance were
selected for subsequent analysis.
doi:10.1371/journal.pone.0003385.g001
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other hand, there was a much larger proportion of genes which
had their expression level correlated with body weight in the VAT
than in the SCAT. These gene expression data are now described
separately for each type of analysis.
Genes regulated by high fat diet irrespective of body
weight gain. In the VAT, there were 41 genes that were up-
regulated and 85 that were down-regulated by HFD feeding,
irrespective of body weight gain (Figure 6A). Among the up-
regulated genes there was a significant over-representation of
genes involved in ‘‘cytoskeleton/cell projection biogenesis’’
(Table 1, and Table S1 for the identity of individual genes).
Among the down-regulated genes, there was a significant
enrichment in genes pertaining to the glycolytic pathway, and to
the fatty acid and steroid biosynthesis pathways (Table 1, and
Table S1) suggesting similar inhibition by HFD of glycolysis,
lipogenesis and steroid biosynthesis in all mouse subgroups.
In SCAT, 342 genes were up-regulated and 175 were down-
regulated similarly in all three subgroups of HFD mice (Figure 6C).
The up-regulated genes contained genes that belonged to the
‘‘cytoskeleton/adhesion’’, ‘‘metabolism’’, ‘‘intracellular signaling’’,
‘‘transport’’ and ‘‘ubiquitination’’ biological functions (Table 1,
and Table S2). Among the down-regulated genes there was
enrichment in genes pertaining to the ‘‘immune response’’,
‘‘ribosome’’ and ‘‘transport’’ categories.
The above data indicated very striking difference of adaptation of
both tissues to HFD with different classes of functions being
modulated in each tissue. Alternatively, some metabolic pathways
were regulated in the same direction but through regulation of
different genes. For instance, ‘‘glycolysis’’ was down-regulated in
VAT, as suggested by the reduced expression of 9 genes, including
hexokinase, phosphofructokinase, pyruvate kinase and pyruvate
dehydrogenase (Table 1 and Table S1), whereas in SCAT, the
‘‘glycolysis’’ class of function was not significantly regulated.
However, the three genes that were down-regulated in the
‘‘transport’’ class of function were Glut1, Glut4 and Glut8, suggesting
decreased capacity for glucose utilization in SCAT through a
decreased uptake capacity. Similarly, the ‘‘fatty acid metabolism’’
genesthat were up-regulated inSCAT contained 10genesencoding
b-oxidation enzymes, suggesting increased fatty acid oxidation
Figure 2. Effect of rimonabant on body weight. After 6 months of diet, mice under NC or HFD mice of the L, M and H groups were treated with
vehicle (open squares) or rimonabant (closed squares) for one month while maintained on the same diet and. The body weight of each mouse was
monitored every 2–3 days during this treatment. Results are expressed as mean6SD, n=6. p-values indicate statistical significance for the
comparison of body weight between vehicle and rimonabant treatments using t-test following a test of variance homogeneity (F-test).
doi:10.1371/journal.pone.0003385.g002
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palmitoyltransferase 1) and Acadm (Acetyl-Coenzyme A dehydroge-
nase, medium chain) genes were increased in VAT (not shown).
Genes regulated by high fat diet in proportion to body
weight gain
We next searched among the genes that were significantly
regulated by HFD feeding in the L, M and H groups those whose
expression level was correlated with body weight.
In VAT, linear regression analysis identified 77 genes (89
probesets) that were positively correlated with body weight and 10
(11 probesets), which were negatively correlated (Figure 6B).
Figure 7 shows the expression pattern of these genes in each group
and their classification in specific biological functions. Strikingly, a
large proportion of the genes positively correlated with body weight
(23 genes) encoded proteins pertaining to the ‘‘cytoskeleton/
adhesion/motility and extracellular matrix’’ biological functions
and thus involved in maintaining cell and tissue structure. Other
genes encoded proteins involved in ‘‘growth/proliferation/differ-
entiation’’ (5 genes), ‘‘regulation of transcription’’ (6 genes),
‘‘signaling’’ (11 genes) and ‘‘splicing/protein biosynthesis’’ (5 genes).
Only 8 metabolic genes had their expression level correlated with
body weight: stearoyl-Coenzyme A desaturase 2 (Scd2) and malic
enzyme, which are involved in lipogenesis, had markedly reduced
expression levels in the L group and close to normal expression in
the H group as compared to the NC control; acetylCoA
dehydrogenase, medium chain (Acadm), lysophosphatidyl glycerol
acyl transferase (Lpgat1), caveolin1 (Cav1), CD36, oxysterol-binding
protein-like 8 (Osbpl8), lipopolysaccharide binding protein (Lbp),
polymerase I and transcript release factor (Ptrf) were positively
correlated with body weight.
In SCAT, only 8 genes were positively and 3 negatively correlated
with body weight (Figure 6D and Figure 8). They belonged to cell
Figure 3. Effect of rimonabant on glycemia and insulin, leptin and VLDL plasma concentrations. At the end of the 1-month rimonabant
or vehicle treatment, glycemia (A), plasma insulin (B), leptin (C) and VLDL (D) were measured in the fasted state in the normal chow (NC) or in the HFD
fed mice of each subgroup. Results are expressed as mean6SD (number of mice/measurement: 3–9).
doi:10.1371/journal.pone.0003385.g003
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cathepsin L, protocadherin7, cadherin EGF LAG seven pass G-type
receptor 2), and to various function but not to ‘‘metabolism’’.
Together the above data suggest that in VAT, two different
transcriptional programs were induced by HFD feeding. One
controls metabolic adaptation by down-regulating lipid and steroid
biosynthesis and glucose catabolism, and by increasing free fatty acid
beta-oxidation. This program is regulated irrespective of body weight
and adipocytes size. The second one, constituted by genes whose
expression was correlated with body weight, controls the adipocyte
cytoarchitecture and extracellular matrix. The increased expression
of genes implicated in differentiation, growth and proliferation,
regulation of transcription, splicing and biosynthesis, also suggests
that recruitment and differentiation of adipocyte precursors contrib-
utes to fat mass expansion. In contrast, in SCAT, the ‘‘metabolism’’
and ‘‘structure’’ genes were mostly regulated irrespective of body
weight. These two fat depots therefore respond to the HFD with very
different transcriptional programs, even though they show similar
adipocyte hypertrophy with increasing body weight.
GSEA analysis
As a separate bioinformatics analysis, GSEA was performed to
identify genesets enriched in VAT and SCAT of mice from the
H compared to the NC group (Table 2 and Table S3).
Figure 4. Effect of HFD and rimonabant treatment on adipocyte cross sectional area in VAT and SCAT. The figure shows the average
cross-sectional area of adipocytes from the L (red), M (green) and H (blue) groups and from the NC fed mice (black), as measured on adipose tissue
sections ($420 adipocytes measured per tissue). A, B: adipocytes from VAT after vehicle or rimonabant treatment, respectively. C, D, adipocytes from
SCAT after vehicle or rimonabant treatment, respectively. Increased body weight correlated with increased adipocytes cross-sectional areas.
rimonabant treatment restored normal size distribution.
doi:10.1371/journal.pone.0003385.g004
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in genes belonging to the p38 and JNK MAP kinase pathways
(ST_p38_MAPK_Pathway, in VAT and ST_JNK_MAPK_Path-
way, in VAT and SCAT), which are known to be involved in
adipogenesis [38,39], and a specific gene set related to cell
differentiation (ST_Differentiation_Pathway_in_PC12_ Cells) in
both tissues. Interestingly, the leading edge genes for the JNK
pathway were largely different between the two adipose tissues, with
Figure 5. Data analysis workflow. Normalized microarray data were filtered based on spot quality and incomplete annotation and used for Gene
Set Enrichment Analysis (GSEA). Alternatively, statistical analysis was performed to reveal the effect of HFD feeding on gene expression irrespective of
body weight, i.e., considering the mice from the L, M, and H group as a single group (‘‘grouped analysis’’). Separately, genes specifically regulated in
the L, M, and H groups as compared to the NC group were identified to determine, by linear regression analysis, those whose expression level
correlated with body weight (’’individual analysis’’). Genes regulated by rimonabant were selected by comparing their expression level separatelyi n
the L, M or H mice treated or not with rimonabant.
doi:10.1371/journal.pone.0003385.g005
Transcriptomics of Fat Growth
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3385Figure 6. High fat diet feeding induces differential regulation of gene expression in VAT and SCAT. The figure illustrates the numbers of
genes that are similarly regulated in the L, M and H groups, irrespective of body weight gain (A, C) or whose expression is positively or negatively
correlated with body weight (B, D) in the VAT (A,B) and SCAT (C,D). The two tissues behaved very differently, with the VAT having a larger number of
genes whose expression was correlated with body weight than SCAT. SCAT, however, had a much greater number of genes regulated by HFD but
most were similarly regulated irrespective of body weight. Data are expressed as the mean of M values calculated for each gene in each group (n=4–
5 mice). Red lines represent genes, which were negatively correlated with body weight.
doi:10.1371/journal.pone.0003385.g006
Table 1. Biological functions enriched in the groups of genes that were similarly regulated by HFD in the L, M and H in VAT or in
SCAT (‘‘Grouped analysis’’).
Tissue Regulation Biological function P-value
VAT UP Cytoskeleton/Cell projection biogenesis (motility) 2.9E-02/6.9E-03
DOWN Carbohydrate metabolism 7.6E-12
Glycolysis 1.8E-10
Glycogen metabolism 1.5E-03
Pyruvate metabolism 5.3E-05
Lipid metabolism 2.3E-07
Steroid metabolism (cholesterol biosynthesis) 1.3E-05
Fatty acid metabolism 2.7E-04
SCAT UP Cytoskeleton/Adhesion Cell junction 3.2E-03
Cytoskeleton 2.1E-03
Metabolism Lipid metabolism 5.0E-02
Fatty acid metabolism 2.4E-06
Coenzyme metabolism 6.5E-03
Intracellular signaling Small GTPase 1.9E-03
dephosphorylation 2.6E-02
Transport Intracellular transport protein 3.9E-03
Ubiquitin pathway Ubl conjugation pathway 3.2E-02
DOWN Immune response 1.5E-03
Ribosome 3.5E-04
Transport Glucose transport 5.8E-03
doi:10.1371/journal.pone.0003385.t001
Transcriptomics of Fat Growth
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eight common genes (Table S3). For the PC-12 Differentiation set
there were 15 leading edge genes in VAT and 19 in SCAT and 13
were common.
Genesets associated with regulation of cytoskeleton and
extracellullar matrix (CR_CAM) as well as migration/motility
(EMT_UP) processes were enriched only in VAT of the H mice,
which also showed an interesting enrichment in the SFT geneset.
This geneset is enriched in genes for the extracellular matrix and
some remodelling enzymes and is considered as a signature of
activated tissue stroma [40] (Table 2 and Table S3). This further
suggested that the expansion of the adipose tissue was associated
with cell proliferation and rearrangement of the cytoskeleton, the
extracellular matrix and the participation of stromal cells.
In SCAT, GSEA identified an enrichment in genes controlling
glycerolipid metabolism (MAP00561_Glycerolipid_metabolism)
and genes regulated by retinoic acid (RAR_UP).
Together the above data indicated that very different mecha-
nisms operate during fat mass expansion in VAT and SCAT. In
particular, there was a differential activation of the MAP kinase
pathway and, in VAT, a more extensive remodeling of cell
structure and extracellular matrix and an important participation
of its stromal environment.
Rimonabant effect on VAT and SCAT gene expression
Rimonabant treatment normalized body weight (Figure 2) and
adipocyte cross-sectional area in both VAT and SCAT (Figure 4B,
D). To analyze the effect of rimonabat on gene expression we
focused our analysis on the obese (H) group of mice, treated with
rimonabant or vehicle. In VAT from these mice, among the 595
genes that were regulated by HFD, 206 genes had their expression
normalized by rimonabant treatment and these belonged to each
class of biological function (Table S4). Among the genes whose
expression was correlated with body weight (Figure 7), 64% (56
out of 87) had their expression normalized by rimonabant
treatment. They also fell into each class of function. In the groups
of genes that were similarly regulated in the three HFD groups,
only 6% (7 out of 115) had their expression normalized by
rimonabant (Table S1). Three belonged to the glycolysis pathway:
Glut4, phosphomannomutase, pyruvate carboxylase; the other
were fatty acid synthase, a sialyltransferase (Siat10), a DEAD box-
containing protein (Ddx27) and a Riken clone (4930504E06).
In the SCAT from obese H mice, among the 698 genes that
were regulated by HFD, 186 genes had their expression
normalized by rimonabant treatment. Among the genes whose
expression was correlated with body weight (Figure 8), 81% (9 out
of 11) had their expression normalized by rimonabant treatment.
In the group of genes that were similarly regulated in the three
HFD groups, 17% (87 of the 517) had their expression normalized
by rimonabant treatment (Table S2).
We next performed GSEA on gene expression data from the
adipose tissues of mice from the HFD (H group) and NC group
treated with rimonabant. Two major observations were made.
Firstly, in both VAT and SCAT, the genesets that were detected
by GSEA in comparing the adipose tissues of HFD vs. NC fed
mice were no longer detected. Secondly, new gensets were
identified in each adipose tissue. In VAT, there was an up-
regulation of a ‘‘mRNA splicing’’ gene set, whereas, interestingly,
in SCAT there was an up-regulation of glucose-sensitive genes
(GLUCOSE_DOWN) and, intriguingly, a down-regulation of two
sets of genes encoding oxidative phosphorylation proteins
(VOXPHOS and Electron_Transport_Chain) (Table 2). As
presented in Table S3, there was a coordinated decreased
expression of a total of 35, 14, 3, 6, and 9 genes encoding
subunits of, respectively, complexes I to V. Thus, GSEA indicated
a near-normalization of the transcripts expressed in each tissue
after rimonabant treatment, with however, indication that changes
in mRNA splicing accompanied normalization of VAT structure
and function whereas SCAT normalization was associated with an
increased sensitivity to glucose and decreased oxidative phosphor-
ylation.
Discussion
Here, we used C57Bl/6 mice fed a high fat diet, and which
develop different degrees of obesity, to analyze the differential
adaptation of visceral and subcutaneous fat to HFD feeding and
the mechanisms associated with rimonabant-induced body weight
normalization. Bioinformatic analysis of our transcriptomic data
revealed very different behaviors of both adipose tissues. These
differences indicated different transcriptional control of genes
involved in nutrients metabolism, in the control of adipocytes
precursor recruitment and differentiation, as well as in the control
Figure 7. Gene whose expression was correlated with body weight in VAT and their correction by rimonabant treatment. The genes
that were selected by linear regression analysis for positive or negative correlation with body weight were classified according to biological function
categories and their expression level was displayed for each mouse with red: increased expression, green: decreased expression as compared to NC
fed mice. * indicates genes whose expression was significantly regulated by rimonabant in the H group.
doi:10.1371/journal.pone.0003385.g007
Figure 8. Gene whose expression was correlated with body weight in SCAT and their correction by rimonabant treatment. The genes
that were selected by linear regression analysis for positive or negative correlation with body weight are displayed for each mouse with red: increased
expression, green: decreased expression as compared to NC fed mice. * indicate genes whose expression was significantly regulated by rimonabant
in the H group.
doi:10.1371/journal.pone.0003385.g008
Transcriptomics of Fat Growth
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body weight and adipocytes size by rimonabant treatment
normalized the expression of most genes in both tissues with,
however, a striking coordinated down-regulation of oxidative
phosphorylation genes in SCAT and up-regulation of mRNA
splicing activity in VAT.
Genes regulated by HFD and correlated or not with body
weight
In VAT, genes regulated by HFD in the L, M and H groups,
showed similar down-regulation of a large set of genes coding for
enzymes of glycolysis, lipogenesis and steroid biosynthesis and up-
regulation of b-oxidation genes, Cpt1a and Acadm. Linear
regression analysis of gene expression and body weight revealed
a large number of genes encoding proteins of the extracellular
matrix and the cytoskeleton (Figure 6). Thus, the differential fat
tissue expansion observed in C57Bl/6 mice under HFD was
associated with up-regulation of a large group of genes required for
reorganization of the interaction between the adipocyte cytos-
tructure and its tissue environment. Fat tissue expansion was also
associated with increased expression of several genes involved in
lipid transport, uptake and storage, and which have previously
been correlated with lipid accumulation and fat cell enlargment,
Cav1, CD36, Mest, Fgf1, Gdf15 [37,41–43].
In SCAT, as compared to VAT, many more genes were up- or
down-regulated similarly in all three mouse subgroups and only 8
genes were correlated with body weight. Seventeen ‘‘structure’’
genes were similarly regulated in the three subgroups by HFD and
three had expression levels positively correlated with body weight
(annexin2, protocadherin 7, cathepsin L) whereas the seven-pass
cadherin-EGF protein (Celsr2), involved in homophilic cell-cell
interactions, showed negative correlation with body weight. Thus,
as reported in several previous studies [7,37,44,45], remodeling of
the interaction between the adipocyte cytoskeleton, integrins, and
extracellular matrix proteins is a key event in fat cell expansion,
which is also associated with angiogenesis required for adipose
tissue development. Our data, however, indicate that this tissue
remodeling process proceeds differently in both subcutaneous and
visceral fat. In particular, whereas there is a striking correlation
between fat cell enlargement and expression of these ‘‘structure’’
genes in VAT, this is not the case in the SCAT where most of
these genes are increased even when adipocytes are small. The
basis for this differential response is not known but may be related
to both tissues originating from different types of precursor cells,
having different differentiation potential [26,27].
Another interesting difference between both tissues is in the
regulated expression of ‘‘metabolic’’ genes. For instance, gene
expression data suggest that glycolysis was decreased in both
tissues. However, in the VAT this was associated with a down-
regulation of several genes encoding glycolytic enzymes, whereas
in SCAT there was only a reduction in the glucose transporters
Glut1, Glut4 and Glut8. Similarly, fatty acid synthesis appeared to
be reduced in both tissues as a consequence of reduced expression
of 8 fatty acid synthesis genes in VAT and only 2 in SCAT, with
Fasn being reduced in both tissues. For the fatty acid b-oxidation
only Cpt1a and Acadm was increased in VAT and 10 in SCAT
(including Cpt1a). Thus, adipocytes from both tissues appear to
modulate major nutrient metabolism pathways in the same
direction but using different gene expression responses.
Gene set enrichment analysis of VAT and SCAT
GSEA provided complementary information about the mech-
anisms of VAT and SCAT adaptation to high fat diet in the H as
T
a
b
l
e
2
.
B
e
s
t
g
e
n
e
s
e
t
s
o
b
t
a
i
n
e
d
b
y
G
S
E
A
f
o
r
t
h
e
c
o
m
p
a
r
i
s
o
n
o
f
N
C
a
n
d
H
g
r
o
u
p
s
t
r
e
a
t
e
d
w
i
t
h
s
a
l
i
n
e
(
N
C
v
s
.
H
)
o
r
R
i
m
o
n
a
b
a
n
t
(
N
C
T
v
s
.
H
T
)
i
n
V
A
T
a
n
d
i
n
S
C
A
T
.
T
i
s
s
u
e
C
o
m
p
a
r
i
s
o
n
R
e
g
u
l
a
t
i
o
n
o
f
g
e
n
e
s
G
e
n
e
s
e
t
n
a
m
e
N
u
m
b
e
r
o
f
m
a
t
c
h
e
d
g
e
n
e
s
f
r
o
m
g
e
n
e
s
e
t
N
u
m
b
e
r
o
f
l
e
a
d
i
n
g
e
d
g
e
g
e
n
e
s
N
o
r
m
a
l
i
z
e
d
e
n
r
i
c
h
m
e
n
t
s
c
o
r
e
(
N
E
S
)
p
-
v
a
l
u
e
V
A
T
N
C
v
s
.
H
u
p
i
n
H
S
T
_
p
3
8
_
M
A
P
K
_
P
a
t
h
w
a
y
2
3
1
2
2
.
2
2
0
.
0
0
0
u
p
i
n
H
S
T
_
J
N
K
_
M
A
P
K
_
P
a
t
h
w
a
y
2
3
1
3
1
.
9
4
0
.
0
0
4
u
p
i
n
H
S
T
_
D
i
f
f
e
r
e
n
t
i
a
t
i
o
n
_
P
a
t
h
w
a
y
_
i
n
_
P
C
1
2
_
C
e
l
l
s
2
4
1
5
1
.
7
7
0
.
0
1
3
u
p
i
n
H
C
R
_
C
A
M
(
C
a
n
c
e
r
-
r
e
l
a
t
e
d
g
e
n
e
s
i
n
v
o
l
v
e
d
i
n
c
e
l
l
a
d
h
e
s
i
o
n
a
n
d
m
e
t
a
l
l
o
p
r
o
t
e
i
n
a
s
e
s
)
4
2
2
5
1
.
8
0
.
0
1
4
u
p
i
n
H
E
M
T
_
U
P
(
E
p
i
t
h
e
l
i
a
l
-
t
o
-
m
e
s
e
n
c
h
y
m
a
l
t
r
a
n
s
i
t
i
o
n
)
3
3
1
3
1
.
7
8
0
.
0
1
8
u
p
i
n
H
S
F
T
(
S
o
l
i
t
a
r
y
F
i
b
r
o
u
s
T
u
m
o
r
)
6
5
3
3
1
.
5
1
0
.
0
5
4
N
C
T
v
s
.
H
T
u
p
i
n
H
T
m
R
N
A
s
p
l
i
c
i
n
g
2
9
2
3
1
.
8
7
0
.
0
0
9
S
C
A
T
N
C
v
s
.
H
u
p
i
n
H
M
A
P
0
0
5
6
1
_
G
l
y
c
e
r
o
l
i
p
i
d
_
m
e
t
a
b
o
l
i
s
m
2
3
1
0
1
.
8
5
0
.
0
0
6
u
p
i
n
H
R
A
R
_
U
P
(
G
e
n
e
s
u
p
r
e
g
u
l
a
t
e
d
b
y
r
e
t
i
n
o
i
c
a
c
i
d
r
e
c
e
p
t
o
r
)
2
2
1
2
1
.
7
6
0
.
0
1
4
u
p
i
n
H
S
T
_
J
N
K
_
M
A
P
K
_
P
a
t
h
w
a
y
2
0
1
5
1
.
5
1
0
.
0
4
5
u
p
i
n
H
S
T
_
D
i
f
f
e
r
e
n
t
i
a
t
i
o
n
_
P
a
t
h
w
a
y
_
i
n
_
P
C
1
2
_
C
e
l
l
s
2
2
1
9
1
.
5
8
0
.
0
5
3
N
C
T
v
s
.
H
T
u
p
i
n
H
T
G
L
U
C
O
S
E
_
D
O
W
N
8
1
5
1
1
.
8
1
0
.
0
0
6
d
o
w
n
i
n
H
T
V
O
X
P
H
O
S
4
8
3
9
2
2
.
0
2
0
.
0
1
9
d
o
w
n
i
n
H
T
E
l
e
c
t
r
o
n
_
T
r
a
n
s
p
o
r
t
_
C
h
a
i
n
5
1
3
8
2
1
.
9
3
0
.
0
3
3
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
0
3
3
8
5
.
t
0
0
2
Transcriptomics of Fat Growth
PLoS ONE | www.plosone.org 10 October 2008 | Volume 3 | Issue 10 | e3385compared to the NC group. Firstly, there was a significant
enrichment in genes implicated in the JNK MAP kinase pathway
in both tissues and of the p38 pathway only in VAT. The MAP
kinase pathways are known to be involved in adipogenesis but
their exact contribution is still partially controversial [38]. For
instance, the p38 MAP kinase has been proposed to activate
adipogenesis [46,47] whereas more recent evidence indicates that
it rather inhibits adipogenesis [48]. The JNK pathway is activated
in adipose tissue of obese animals and JNK
2/2 mice are resistant
to diet-induced obesity [39], thus this pathway may be required for
adipose tissue growth in obesity, consistent with our observation
that the JNK pathway is activated in both tissues. Strikingly
however, only approximately half of the genes in the leading edge
of the JNK pathway geneset were common to VAT and SCAT,
further supporting the existence of various molecular mechanisms
to control the same biological process.
Secondly, GSEA showed an enrichment in VAT, but not in
SCAT, of genes from the ‘‘EMT -UP’’ geneset. This contains
genes expressed during embryonic development and in patholog-
ical epithelial-to-mesenchymal differentiation associated with
malignant tumor progression and metastasis [49,50]. GSEA also
identified the SFT gene set in the VAT of the obese (H) mice. This
gene set was originally derived from the study of different
fibroblastic tumors, solitary fibrous tumors (SFT) and desmoid-
type fibromatosis (DFT) [40]. Both tumors are derived from
fibroblasts and consist of cells with similar morphology but
different behavior, the DFT tumors being more aggressive. These
fibroblastic tumors were analyzed by micorarray analysis and
genesets were identified that distinguished the two forms of
tumors. The SFT gene set was enriched in genes for the
extracellular matrix and some remodelling enzyme whereas the
DTF gene set was enriched for genes characteristic of a fibrotic
response and with activation of the TGF and Wnt signaling
pathways. These signatures therefore provide evidence that the
tissue stroma may follow different patterns of differentiation
involving distinct activation of extracellular matrix proteins,
remodeling enzymes and growth and differentiation response.
The presence of the SFT geneset in the VAT but not the SCAT
therefore indicates that expansion of the visceral fat is associated
with a specific pattern of activation of the tissue stroma. As a
recent report suggests that the SFT geneset may also contain a
signature for the presence of mesenchymal stem cells [51]. This
further suggests that the process of adipogenesis and precursor
recruitment may be different between these two tissues. Thus our
statistical analysis provides indication that expansion of the visceral
and subcutaneuous tissues in obesity is not only directed by
adipocyte-specific responses but also by the close interaction
between the adipocytes and their stromal environment. This may
contribute to the specific function of the differentiated adipocytes
in each fat depot.
Effect of rimonabant treatment
Rimonabant treatment normalized the body weight of mice
under HFD and improved basal glycemia, and plasma insulin,
leptin and VLDL concentrations, in line with previous reports
[52,53]. Statistical analysis of gene expression indicated that
expression of a large proportion of the ‘‘structure’’ and many of
the ‘‘lipid metabolism’’ genes were normalized in VAT and SCAT
of obese mice. GSEA of genes expressed in VAT or SCAT of the
H and NC mice after rimonabant treatment indicated normali-
zation of gene expression. In particular, the geneset related to
proliferation, differentiation, and tissue remodeling/plasticity
processes were no longer detected (Table 2), which suggests that
rimonabant reduces adipose tissue differentiation, in agreement
with a previous report [24]. In VAT there was an increased in the
‘‘mRNA splicing’’ geneset upon rimonabant treatment. This set is
enriched in several genes encoding regulators of gene splicing
(Table S3). Thus, expansion of adipose tissue during obesity or its
normalization by rimonabant treatment may require not only
changes in level of expression of many genes but also the
production of new protein isoforms issued from differential mRNA
splicing. The identity of the concerned genes is, however, not yet
known.
Very interestingly also, GSEA showed a decreased expression of
genes involved in oxidative phosphorylation in SCAT. This was
surprising as decreased expression of oxidative phosphorylation
genes in muscle and adipose tissue was reported to correlate with,
and inferred to cause insulin resistance and type 2 diabetes [54–
57]. However, in a very recent report [58], the link between
reduced oxidative phosphorylation and whole body glucose
metabolism was directly addressed by studying mice with tissue-
specific deletion of the AIF gene, which leads to reduced
expression of electron transport chain genes to a level similar to
that reported in studies of type 2 diabetic patients [54,55]. The
consequence of this deregulation was, however, to confer greater
insulin sensitivity and to protect the mice against diet-induced
obesity. This was explained by the requirement for a greater
utilization of nutrients to generate a lower amount of ATP when
the oxidative phosphorylation capacity was decreased. It is thus
very striking that in the SCAT a very large number of oxidative
phosphorylation genes were deregulated by rimonabant treatment.
Thus, rimonabant may control body weight, in part at least, by
down-regulating oxidative phosphorylation genes, an event that is
specific to SCAT.
We did not detect changes in oxidative phosphorylation genes
expression in the VAT of HFD or HFD and rimonabant treated
mice. This is in contrast with a recent report showing that
oxidative phosphorylation genes were down-regulated by HFD
and increased by rimonabant treatment [59]. However, this study
was performed with epididymal fat whereas we studied omental fat
and the different observations may be related to the different
visceral fat depots analyzed, as well as to differences in high fat diet
composition. It is also worth noting,that rimonabant had no
significant effect on gene regulation in the adipose tissue of NC fed
mice.
Concluding remarks
It is important to note that we studied whole adipose tissue
depots and not isolated adipocytes. Thus, our data provide
information on the adaptation of each adipose tissue to HFD
feeding and it is not possible to strictly define which genes are
expressed specifically in adipocytes as compared to those expressed
in various stromal cells including mesenchymal stem cell,
preadipocytes, fibroblasts, inflammatory or endothelial cells.
However, our statistical analysis of the microarray data, offers a
unique way at looking at the specific adaptation of both VAT and
SCAT to HFD and their normalization by CB1 antagonism.
We observed, in VAT, that ‘‘metabolic’’ genes were similarly
regulated independently of body weight whereas the ‘‘structure’’
genes had expression levels correlated with increased body weight
and fat cell size. This indicated a need for reorganization of
cytoarchitecture, extracellular matrix and for the activation of the
tissue stroma during fat mass expansion. In the SCAT a larger
number of genes were up- or down-regulated by HFD than in
VAT, but most of these genes were regulated irrespective of body
weight gain and GSEA suggested a less active adipogenesis and no
major involvement of the tissue stroma. Blockade of CB1 receptor
activity suggested a striking decreased in oxidative phosphoryla-
Transcriptomics of Fat Growth
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An interesting challenge of future research will be to analyze the
basis for the differential response of these two tissues, in particular,
whether this is due to differences between the interaction of
(pre)adipocytes with their stromal environment or to adipocytes
originating from distinct precursors with different capacity to
respond to the high fat diet, or a combination of both. In addition,
our data may help identify new targets for the selective regulation
of the function and expansion of either the subcutaneous or
visceral fat in obesity.
Materials and Methods
Animals and treatments
Six-week-old C57BL/6J male mice (Janvier, France) were fed a
normal chow (NC; 12% fat, 28% protein, and 60% carbohydrate)
or a high fat diet (HFD; 72% fat, 28% protein, and ,1%
carbohydrate) for 7 months. Their body weight and tolerance to
intraperitoneal glucose injections (1 g/kg body weight) (AUC: area
under the curve) were determined after 3, 6 and 7 months of HFD
as described previously [35]. After 6 months of HFD, mice with
AUC values of 920–1400 mM.min were selected. These mice
were divided into 3 groups based on their body weight (Figure 1).
Eighteen NC mice were also selected. Each mouse was treated
with vehicle (0.1% Tween 80 (Fluka) in H2O) or rimonabant
(10 mg.kg
21.day
21) administrated by gavage daily for 1 month.
Vehicle or rimonabant treatments were randomly assigned in each
group of NC and HFD mice. The body weight of mice under
treatment was monitored every 2–3 days. At the end of the
treatment, omental (VAT) and subcutaneous (SCAT) adipose
tissues, as well as plasmas, were collected and immediately frozen
in liquid nitrogen. The animal experiments have been approved
by the Service Ve ´te ´rinaire Candonal of the Canton de Vaud.
Plasma measurements
Leptin and insulin plasma concentrations were assessed by
ELISA (Mouse Adipokines from LINCO) using the Luminex
system (Biorad). Free fatty acids (FFA), HDL, LDL, cholesterol,
triglycerides (TG) concentrations were measured enzymatically
with commercial kits (FFA: nu999–75406 from Wako Pure
Chemicals Industries; HDL-C plus: nu03030024, LDL-C plus:
nu03038661, cholesterol: nu12016630; TG: nu12016648 from
Roche Diagnostic), using a Hitachi robot 902 (Roche). Glycemia
were measured from tail vein blood using a Glucometer
(Glucotrend Premium; Boehringer Mannheim GmbH).
Adipocyte area measurement
Sections (20 mm) of visceral and subcutaneous adipose tissue
were cut with a cryostat at 230uC, fixed in 10% paraformalde-
hyde for 10 minutes and stained with hematoxilin-eosin. Cross-
sectional area were measured on 420 cells/group using a Carl
Zeiss AxioVision program.
RNA preparation, labeling and hybridization on cDNA
microarrays
RNA from 5 different mice per group was extracted from
visceral and subcutaneous adipose tissues using peqGOLD
Trifast
TM (peqlab) and chloroform-isoamylalcool (24:1) extraction.
RNA was precipitated with isopropanol and purified by passage
over RNeasy columns (Qiagen). RNA quality was checked before
and after amplification with a Bioanalyzer 2100 (Agilent). RNA
was reverse transcribed and RNA was amplified with Messa-
geAmp
TM kit (Ambion). A Mouse Universal Reference (Clontech)
was similarly amplified and both adipose tissue and reference
RNAs were labeled by an indirect technique with Cy5 and Cy3
according to published protocols [60]. Labeled RNAs were
hybridized to microarrays containing 17664 cDNAs prepared at
the DNA Array Facility of the University of Lausanne. Scanning,
image, and quality control analyses were performed as previously
published [60]. Data were expressed as log2 intensity ratios (Cy5/
Cy3), normalized with a print tip locally weighted linear regression
(Lowess) method and filtered based on spot quality and incomplete
annotation. All analysis were performed with the R software for
statistical computing available at the Comprehensive R Archive
Network (cran.us.r-project.org/).
Analysis of gene expression and statistics
The flow chart for data analysis is described in figure 5.
Statistically differentially expressed genes were identified using the
limma package from Bioconductor (http://www.bioconductor.
org). Gene Set Enrichment Analysis (GSEA) was performed
directly using filtered data from VAT or SCAT of the different
mouse groups (http://www.broad.mit.edu/gsea/msigdb/genesets.
jsp?collection=C2) [61]. The ranking of genes was based on t-
statistic values calculated by limma.
KEGG pathway or Gene Ontology analysis were carried out
using DAVID (http://david.abcc.ncifcrf.gov)[62].
Statistical comparisons of plasma insulin, leptin and VLDL were
performed using a one-way analysis of variance followed by a
Tukey post-hoc test (SPSS). The statistical significance for the
comparison of body weight curves obtained in the presence of
vehicle or rimonabant treatment for NC or HFD subgroups was
evaluated with linear models with repeated measures using SPSS
program. Statistical significance for the comparison of body weight
between vehicle and rimonabant treatments at day-23 was
assessed by a Student’s t-test after a variance homogeneity test
(F-test).
The microarray data have been deposited in the GEO data base
under ID nu GSE11790.
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